Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Borowitz

Showing results (61-70 of 145) with videos related to

Pageof 15
Sort By:
Blood|January 10, 2008
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology GroupStella M Davies, Michael J Borowitz, Gary L Rosner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Blood|June 12, 2012
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemiaSarah K Tasian, Michelle Y Doral, Michael J Borowitz, et al.
Blood|April 5, 2008
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyMichael J Borowitz, Meenakshi Devidas, Stephen P Hunger, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Blood|July 11, 2006
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyDeepa Bhojwani, Huining Kang, Naomi P Moskowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2013
Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalitiesMatthew P Tilson, Richard J Jones, Amy Sexauer, et al.
Archives of Pathology & Laboratory Medicine|February 23, 2017
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of HematologyDaniel A Arber, Michael J Borowitz, Melissa Cessna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignanciesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Pageof 15

Showing results (61-70 of 145) with videos related to

Sort By:
Pageof 15
Blood|January 10, 2008
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology GroupStella M Davies, Michael J Borowitz, Gary L Rosner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Blood|May 6, 2010
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupKelly W Maloney, William L Carroll, Andrew J Carroll, et al.
Blood|June 12, 2012
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemiaSarah K Tasian, Michelle Y Doral, Michael J Borowitz, et al.
Blood|April 5, 2008
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyMichael J Borowitz, Meenakshi Devidas, Stephen P Hunger, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Blood|July 11, 2006
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyDeepa Bhojwani, Huining Kang, Naomi P Moskowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2013
Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalitiesMatthew P Tilson, Richard J Jones, Amy Sexauer, et al.
Archives of Pathology & Laboratory Medicine|February 23, 2017
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of HematologyDaniel A Arber, Michael J Borowitz, Melissa Cessna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignanciesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Pageof 15